Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Canadian‑incorporated biopharmaceutical issuer listed in the United States. Aurinia files annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K, along with exhibits such as earnings releases and investor presentations.
Recent Form 8‑K filings referenced in the available data show how Aurinia uses current reports to furnish quarterly financial results, updates on its share repurchase plan and key clinical developments. For example, the company has filed 8‑Ks to furnish earnings releases for quarters ended March 31, June 30 and September 30, 2025, and to report positive Phase 1 results for aritinercept (AUR200), its dual BAFF and APRIL inhibitor. These filings often attach press releases and presentations as exhibits, providing additional context on revenue, net product sales of LUPKYNIS (voclosporin), license and collaboration revenue, and operating expenses.
Through its periodic reports, Aurinia discloses condensed consolidated balance sheets, statements of operations and cash flows, detailing items such as cash, investments, inventory, lease liabilities, deferred revenue and shareholders’ equity. Investors analyzing AUPH can use 10‑K and 10‑Q filings to review the company’s financial position, revenue composition between LUPKYNIS net product sales and collaboration income, and risk factor discussions related to its autoimmune disease focus.
On Stock Titan, these SEC filings are complemented by AI‑powered summaries that highlight the main points of lengthy documents, helping readers quickly identify changes in revenue, profitability, cash flows or capital allocation, such as the expansion of a share repurchase plan. Real‑time updates from EDGAR ensure that new Aurinia 10‑K, 10‑Q, 8‑K and related exhibits, as well as insider transaction reports on Form 4 when filed, are surfaced promptly with simplified explanations for easier review.
Aurinia Pharmaceuticals Inc. reported insider equity activity by Chief Executive Officer Peter Greenleaf. He received a grant of 328,424 employee stock options at an exercise price of $0.0000 per share, with one-third vesting twelve months from the grant date and the remainder vesting in twenty-four equal monthly installments thereafter.
On the same grant date, he also acquired 196,403 shares of common stock through an award. Separately, 100,890 common shares were disposed of to cover tax withholding obligations upon the vesting of restricted stock units. Following these transactions, he directly owned 1,840,379 common shares.
Aurinia Pharmaceuticals Inc. reported that SVP and Chief Medical Officer Greg Keenan received new equity awards on February 27, 2026. He was granted stock options for 67,870 shares at an exercise price of $0, increasing his option holdings to 67,870 shares.
He also acquired 40,586 shares of common stock as a grant or award at a stated price of $0, bringing his directly held common shares to 162,518. Footnotes explain that related performance rights vest in tranches based on share price targets and time-based vesting schedules.
Aurinia Pharmaceuticals Inc. executive vice president and general counsel Stephen P. Robertson reported multiple equity transactions. On February 27, 2026, he received a grant of 98,813 employee stock options with a $0 exercise price and a separate award of 59,090 common shares, both held directly.
On March 2, 2026, 36,525 common shares were disposed of to satisfy tax withholding obligations upon vesting of restricted stock units, at a price of $14.21 per share. After these transactions, he directly owned 505,861 common shares.
Aurinia Pharmaceuticals reports strong 2025 growth built around its lupus nephritis drug LUPKYNIS and a solid cash position. Net product sales reached $271.3 million, up 25% from 2024, driven by U.S. specialty pharmacy distribution and supply to its partner Otsuka for Europe and Japan.
Cash flows from operating activities rose to $135.7 million, a 206% increase, supporting a year-end cash, cash equivalents, restricted cash and investment balance of $398.0 million. Aurinia repurchased 12.2 million common shares for $98.2 million, reflecting active capital return alongside continued investment in its pipeline.
The company highlights LUPKYNIS’ clinical profile, updated treatment guidelines that favor early aggressive therapy, extensive patent and exclusivity protections, and an expanding autoimmune pipeline led by aritinercept, while acknowledging competitive, patent-challenge and reimbursement risks.
Aurinia Pharmaceuticals reported strong growth for 2025, driven by its lupus nephritis drug LUPKYNIS. Total revenue reached $283.1 million for the year, up 20% from 2024, with LUPKYNIS net product sales rising 25% to $271.3 million.
The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier, helped by a large income tax benefit from releasing a valuation allowance on deferred tax assets. Cash, cash equivalents, restricted cash and investments were $398.0 million as of December 31, 2025, after repurchasing 12.2 million common shares for $98.2 million. For 2026, Aurinia guides to total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million, implying low- to mid-teens percentage growth.
Aurinia Pharmaceuticals Inc. insider activity: Chief Operating Officer Matthew Maxwell Donley reported a tax-related share disposition tied to equity compensation. On this Form 4, 32,901 shares of common stock were withheld at $14.4000 per share to satisfy tax obligations upon the vesting of restricted stock units. This was an automatic tax-withholding disposition, not an open-market trade, and Donley continued to hold 662,900 common shares directly after the transaction.
Aurinia Pharmaceuticals Inc. Chief Executive Officer Peter Greenleaf reported a Form 4 transaction involving company common stock. On February 20, 2026, 100,171 shares were disposed of at $14.40 per share in a tax-withholding disposition, meaning shares were withheld to cover tax obligations upon vesting of restricted stock units rather than sold in an open-market trade. After this transaction, Greenleaf directly owned 1,744,866 common shares.
Aurinia Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller reported a tax-related share disposition. On the vesting of restricted stock units, 32,424 shares of common stock were withheld at $14.40 per share to cover tax obligations, according to the footnote. After this withholding transaction, Miller directly owned 556,703 common shares.
Aurinia Pharmaceuticals Inc.'s EVP and General Counsel, Stephen P. Robertson, reported a Form 4 transaction involving company common stock. On February 20, 2026, 34,638 shares of common stock at $14.40 per share were disposed of to satisfy tax withholding obligations tied to vesting restricted stock units, rather than through an open-market sale. After this tax-withholding disposition, Robertson’s directly held ownership stood at 483,296 common shares.
Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation. On 02/02/2026, 11,552 shares of common stock were withheld at $14.53 per share to satisfy tax obligations when restricted stock units vested.
After this tax-related withholding, Keenan beneficially owns 121,932 shares of Aurinia common stock, held directly. The filing reflects an administrative adjustment rather than an open-market purchase or sale, and confirms his ongoing equity stake in the company.